Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
191.31
+1.04 (0.55%)
At close: Oct 30, 2026, 4:00 PM EDT
193.00
+1.69 (0.88%)
After-hours: Oct 30, 2026, 7:41 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
41.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 16.90B |
| BeOne Medicines AG | 6.13B |
| Incyte | 6.01B |
| argenx SE | 5.92B |
| Alnylam Pharmaceuticals | 5.01B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
RVMD News
- 4 days ago - Revolution Medicines to Participate in November 2026 Investor Conferences - GlobeNewsWire
- 9 days ago - Revolution Medicines presents subgroup analyses from RASolute 302 trial - TheFly
- 9 days ago - Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 - GlobeNewsWire
- 10 days ago - Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - GlobeNewsWire
- 12 days ago - Revolution Medicines begins treating patients in RASolve 308 trial - TheFly
- 12 days ago - Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer - GlobeNewsWire
- 13 days ago - Revolution Medicines price target raised to $241 from $240 at Truist - TheFly
- 16 days ago - Revolution Medicines initiated with an Outperform at William Blair - TheFly